

Curriculum Vitae

Personal information Vesna Višekruna Vucina

Work experience

Feb 2019 - present: Head of Department of Immunization, Division for Epidemiology of Communicable Diseases, Croatian Institute of Public Health

April 2014- present: Medical epidemiology specialist at Division for Epidemiology of communicable diseases, Croatian Institute of Public Health

2009-2011: General practice doctor, Health Center Vrbovec, Croatia

2008-2009: Medical Doctor, internship at Clinical Hospital "Sveti Duh", Zagreb, Croatia

Education and training

2020 -present: PhD student a Faculty of Medicine, University of Rijeka, Croatia

2011-2014: specialization in epidemiology; Croatian Institute of Public Health, Croatia

2013: postgraduate university specialist studies in epidemiology, School of Medicine, University of Zagreb, Croatia

2008: Croatian State Exam in Medicine

2001-2007: School of Medicine, University of Zagreb, Croatia

Additional information

Publications

1. V. Višekruna Vučina, S. Kurečić Filipović, N. Kožnjak, V. Stamenić, A. D. Clark, B. Mounaud, J. Blau, C. Hoestlandt, B. Kaić Cost-effectiveness of pneumococcal conjugate vaccination in Croatia, *Vaccine*. 2015 May 7;33 Suppl 1:A209-A218. doi: 10.1016/j.vaccine.2014.12.043. <http://www.sciencedirect.com/science/article/pii/S0264410X1401696X>
2. Kaić B, Tomić B, Nemeth-Blažić T, Kurečić Filipović S, Višekruna Vučina V, Draženović V, Pem Novosel I, Šimunović A, Gjenero-Margan I. Guillain Barré sindrom i cijepljenje protiv gripe HČJZ 2013; 9(33):224-231. 3. Pem Novosel I, Sanja Kurečić Filipović, Ira Gjenero Margan, Bernard Kaić, Marijan Erceg, Vesna Višekruna Vučina: Epidemiologija krpeljnog meningoencefalitisa u Hrvatskoj, 1993.- 2012. godine / Epidemiology of tick-borne encephalitis in Croatia, 1993 - 2012 CROCMID2013, Rovinj 24.-27. listopada 2013 Kurečić-Filipović S, Gjenero-Margan I, Kaić B, Kolarić B, Pem-Novosel I, Višekruna-Vučina V. Djelotvornost cjepiva protiv parotitisa, soj L-Zagreb, u uvjetima niske cirkulacije prirodnog soja virusa mumpsa u populaciji. 3. Hrvatski epidemiološki kongres s međunarodnim sudjelovanjem, Šibenik, 7-9. svibanj, 2015. str 104. 4. Višekruna-Vučina V, Gjenero-Margan I, Kurečić-Filipović S, Pem-Novosel I, Kaić B. Dob primjene kombiniranih cjepiva koja sadrže acelularnu pertusis komponentu i obuhvati prijavljivanja nuspojava u Hrvatskoj 2008-2010. 3. Hrvatski epidemiološki kongres s međunarodnim sudjelovanjem, Šibenik, 7-9. svibanj, 2015. str 125. 5. Pem-Novosel I, Vilbić-Čavlek T, Gjenero-Margan I, Kurečić-Filipović, Aleraj B, Babić-Erceg A, Klobučar A, Kaić B, Miletić-Medved, Jeličić P, Višekruna-Vučina V, Erceg M. Istraživanje prevalencije denge infekcije u Hrvatskoj. 3. Hrvatski epidemiološki kongres s međunarodnim sudjelovanjem, Šibenik, 7-9. svibanj, 2015. str 113. 6. T. Nemeth Blažić, Z. Dominiković, M.L. Kosanović Ličina, V. Višekruna Vučina, L. Kasumović, J. Pavlić Akcija testiranja na HIV u LGBT centru Zagreb (MSM) tijekom europskog tjedna testiranja na HIV 2014. 3. Hrvatski epidemiološki kongres s međunarodnim sudjelovanjem, Šibenik, 7-9. svibanj, 2015. str 110. 7. European Centre for Disease Prevention and Control. Vaccine hesitancy among healthcare workers and their patients in Europe -A qualitative study. Stockholm: ECDC; 2015 (coauthor) <http://ecdc.europa.eu/en/publications/Publications/vaccine-hesitancy-among-healthcare-workers.pdf> 8. Višekruna Vučina V, Kaić B. Registar nuspojava cijepljenja u Hrvatskom zavodu za javno zdravstvo, poglavlje u knjizi Cijepljenje i cjepiva, Medicinska naklada 2017., ISBN 978-953-176-762-0, 31-38 str. 9. Kaić B, Višekruna Vučina V. Program obveznog cijepljenja u Republici Hrvatskoj, poglavlje u knjizi Cijepljenje i cjepiva, Medicinska naklada 2017., ISBN 978-953-176-762-0, 1-9 str. 10. Kaić B, Višekruna Vučina V. Protokol nadoknadnog cijepljenja, poglavlje u knjizi Cijepljenje i cjepiva, Medicinska naklada 2017., ISBN 978-953-176-762-0, 268-280 str. 11. M. Rondy, A. Larrauri, I. Casado, V. Alfonsi, D. Pitigoi, O. Launay, RK Syrjänen, G. Gefenaite, A. Machado, VV Vučina, JK Horváth, I. Paradowska-Stankiewicz, SD Marbus, A. Gherasim, JA Díaz-González, C. Rizzo, AE Ivanciuc, F. Galtier, N. Ikonen, A. Mickiene, V. Gomez, S. Kurečić Filipović, A. Ferenczi, MR Korcinska, R van Gageldonk-Lafeber, I-MOVE+ hospital working group, M. Valenciano Research article: 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project; Eurosurveillance, Volume 22, Issue 30, 27 July 2017. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22842> 12. E. Kissling, M. Rondy, I-MOVE/I-MOVE+ study team Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.7.30464> 13. M. Rondy, O. Launay, J. Castilla, S. Costanzo, JP. Barberà, G. Gefenaite; A. Larrauri; C. Rizzo; D. Pitigoi; R.K. Syrjänen InNHove and IMOVE+ working group Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza <https://www.sciencedirect.com/science/article/pii/S0264410X17308964?via%3Dihub> 14. M. Rondy, E. Kissling, HD Emborg, A. Gherasim, R. Pebody, R. Trebbien, F. Pozo, A. Larrauri, J. McMenamin, M. Valenciano, I-MOVE/I-MOVE+ group Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies <https://www.eurosurveillance.org/docserver/fulltext/eurosurveillance/23/9/eurosurv-23-9->

1.pdf?expires=1538738850&id=id&accname=guest&checksum=EBF1E9AF779EC8A67181CF366CF4B1EE 15. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024 <http://dx.doi.org/10.2807/1560-7917.ES.2024.29.8.2400089> 16. Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study <http://dx.doi.org/10.1111/irv.13243> 17. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I - MOVE primary care multicentre study <http://dx.doi.org/10.1111/irv.13069> 18.

Projects

2022 - ongoing Vebis Lot 5; ECDC studies of vaccine effectiveness against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection among patients presenting to primary care physicians

2015-2022 IMOVE project; Integrated Monitoring of Vaccines in Europe; Monitoring influenza vaccine effectiveness (seasonal and pandemic) in EU/EEA

Memberships

Other Relevant Information